• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is EssilorLuxottica (ENXTPA:EL) Quietly Turning Its MedTech Ambitions Into a Core Growth Engine?

    Simply Wall St·07/15/2026 10:32:35
    Listen to the news
    • A recent ophthalmology devices market report highlighted rising demand for minimally invasive procedures and laser vision correction, profiling EssilorLuxottica alongside peers as a key player in meeting these trends.
    • An interesting angle is EssilorLuxottica’s exposure to the growing ophthalmology infrastructure and diagnostic equipment ecosystem, which could deepen its role across broader eye-care solutions beyond traditional eyewear.
    • We’ll now examine how EssilorLuxottica’s positioning in minimally invasive ophthalmology tools informs the existing investment narrative around its MedTech ambitions.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    EssilorLuxottica Société anonyme Investment Narrative Recap

    To own EssilorLuxottica, you generally need to believe in its shift from pure eyewear into broader eye health and MedTech, including minimally invasive ophthalmology tools. The new market report supports this thesis by identifying the company as a key player in devices and laser correction, but it does not materially change the near term catalyst around smart eyewear adoption or the key risk of margin pressure from inflation and costlier innovation.

    Against this backdrop, the recent expansion of the Ray Ban Meta and Oakley Meta lines is particularly relevant, because it highlights EssilorLuxottica’s push into connected eyewear that sits closer to medical devices. As the company leans further into AI enabled glasses and MedTech, the payoff for shareholders will likely hinge on how well these high tech, higher cost products can sustain pricing and volume while the ophthalmology devices opportunity develops.

    Yet even with this MedTech upside, investors should be aware that EssilorLuxottica’s exposure to premium, discretionary products could...

    Read the full narrative on EssilorLuxottica Société anonyme (it's free!)

    EssilorLuxottica Société anonyme's narrative projects €36.9 billion revenue and €3.6 billion earnings by 2029. This requires 9.0% yearly revenue growth and a roughly €1.3 billion earnings increase from €2.3 billion today.

    Uncover how EssilorLuxottica Société anonyme's forecasts yield a €261.48 fair value, a 58% upside to its current price.

    Exploring Other Perspectives

    ENXTPA:EL 1-Year Stock Price Chart
    ENXTPA:EL 1-Year Stock Price Chart

    Compared with consensus, the most pessimistic analysts already expected slower growth, with revenue at about €31.9 billion and earnings of roughly €3.2 billion by 2028, and they worry that rising MedTech complexity and online disruption could pressure margins even if the new ophthalmology device tailwinds materialize.

    Explore 7 other fair value estimates on EssilorLuxottica Société anonyme - why the stock might be worth over 2x more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.